Bipartisan Lawmakers Offer Congressional Bill To Promote Cannabis, CBD Research

A bipartisan group of U.S. senators introduced a federal bill to bolster marijuana and CBD research, a move that could encourage more doctors to recommend medical cannabis and expand legalization efforts.

The bill also would amend the definition of marijuana in the federal Controlled Substances Act to exclude the synthetic equivalent of hemp-derived CBD that contains less than 0.3% THC.

Sens. Dianne Feinstein, a California Democrat, Chuck Grassley, an Iowa Republican, and Brian Schatz, a Hawaii Democrat, introduced the Cannabidiol and Marijuana Research Expansion Act.

“Our combined bill streamlines the research process and paves the way for marijuana-derived medications that are FDA-approved to keep consumers safe,” Feinstein said in a news release, referring to the U.S. Food and Drug Administration.

Grassley and Schatz added that research is necessary to determine the potential medical and health benefits of the substances.

The bill is co-sponsored by a bipartisan group of six U.S. senators. It also has the backing of the American Medical Association.

Some of the bill’s key provisions would:

Expedite and simplify the process for reviewing and approving marijuana research applications.
Streamline the development of FDA-approved substances using CBD and marijuana.
Allow doctors to discuss with adult patients the potential harms and benefits of marijuana and derivatives such as CBD.
Require the Department of Health and Human Services to report to Congress on the potential effects of marijuana on the body, adolescent brain and cognitive abilities.

Original Article Source: https://mjbizdaily.com/bipartisan-lawmakers-offer-congressional-bill-to-promote-cannabis-cbd-research/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Norma Pence

Search This Blog